Maxcyte (MXCT) Receivables (2020 - 2025)
Historic Receivables for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $8.3 million.
- Maxcyte's Receivables rose 8214.91% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 8214.91%. This contributed to the annual value of $4.7 million for FY2024, which is 1896.85% down from last year.
- Latest data reveals that Maxcyte reported Receivables of $8.3 million as of Q3 2025, which was up 8214.91% from $5.8 million recorded in Q2 2025.
- In the past 5 years, Maxcyte's Receivables registered a high of $11.2 million during Q4 2022, and its lowest value of $4.6 million during Q3 2024.
- For the 5-year period, Maxcyte's Receivables averaged around $6.8 million, with its median value being $6.4 million (2021).
- As far as peak fluctuations go, Maxcyte's Receivables tumbled by 4829.53% in 2023, and later surged by 8214.91% in 2025.
- Maxcyte's Receivables (Quarter) stood at $6.9 million in 2021, then surged by 62.5% to $11.2 million in 2022, then tumbled by 48.3% to $5.8 million in 2023, then decreased by 18.97% to $4.7 million in 2024, then skyrocketed by 77.4% to $8.3 million in 2025.
- Its last three reported values are $8.3 million in Q3 2025, $5.8 million for Q2 2025, and $5.5 million during Q1 2025.